MedTech Trends in 2027

Everything is moving at once. Here's where to look.

May 27, 2026

Every year someone publishes a “top trends” list in Medical Technologies. Most people screenshot it, post it on LinkedIn with a 🔥 emoji, and move on with their life.

This year, I want to challenge existing facts and data, mainly because what’s happening in MedTech right now cannot be considered anymore a “trend cycle”.

In the 2026 MedTech Trends Article, I talked about the signals: FDA slowdowns, portfolio break-ups, workforce pressure, surgical robotics opening up and the hospitals being under financial stress.

Those signals? In 2027, they will become the ground.

Here’s what you should be prepared for, whether you’re a Founder, a CEO, an investor, or someone early in their career trying to figure out which table to sit at.

*The views expressed in this article are solely my own and do not represent the position of any organization I am affiliated with. While the projections and analysis presented are informed by publicly available data and referenced sources, they reflect my personal professional judgment and forward-looking perspective. Readers should exercise their own discretion when applying these insights to business or clinical decisions.

1. MedTech AI & regulations

Let me ask you something. Have you ever studied hard all year, then realized you studied the wrong subject one week before the exam? That’s where a large chunk of the industry will be with the European AI Act.

As of August 2027, full compliance obligations for high-risk AI systems (including medical devices) will be in effect. From this date, providers must integrate AI Act obligations directly into their MDR/IVDR conformity processes, ensuring that technical documentation, risk management, and post-market monitoring are aligned under both frameworks.

Think about what that actually means in practice. If you have AI embedded in your device (diagnostic imaging software, a decision-support algorithm, a patient monitoring system), you are now operating under two regulatory frameworks simultaneously: the MDR/IVDR and the AI Act. MedTech groups have been warning that this overlap could slow innovation and complicate compliance if the two frameworks are not harmonized.

The good news? We’re in the transition. And transitions are expensive, but they’re also where you gain or lose ground on competitors.

A parallel transition will shape FDA’s internal structure and how they will be operating next year, by using artificial intelligence based tools to streamline many of their internal processes. If you’re planning to launch or build in USA, you should keep an eye on the progress, as it is expected to have significant reduction of the timeframes for submissions by next year.

What to do: If you haven’t done a GAP analysis against both MDR/IVDR and AI Act requirements, it is time!

2. Surgical Robotics — The era of the specialist robot has arrived

For years, the surgical robotics conversation was basically one name: Intuitive Surgical. That era will be over, and what’s replacing it will be so much more interesting.

The robotic-assisted surgery systems market projection is $12.76 billion in 2026 and is forecast to reach $23.86 billion by 2031 — a 13.33% CAGR, driven by rising demand for minimally invasive procedures, rapid AI integration, and the expansion of 5G-enabled telesurgery networks.

But the number that should actually catch your attention isn’t the headline figure - it’s what’s happening inside it:

neurosurgery is projected to expand at a 16.11% CAGR through 2031, as spine and cranial robots secure regulatory clearances and demonstrate superior accuracy in early outcomes data.

the robotic cardiology surgery market size has grown rapidly in recent years. It is estimated to grow from $0.84 billion in 2025 to $0.98 billion in 2026, with robotic interventions demonstrating reduced procedural risks and enhanced surgical outcomes.
sports medicine is gaining momentum: Oxford’s Podium Institute presented haptic actuator and personalised soft robotic orthosis research at IEEE RoboSoft 2025, demonstrating how rehabilitation robotics and surgical robotics are converging on the same underlying technology (wearable haptic devices, stretchable sensors, personalised orthoses for injury recovery). The athletic population is becoming a serious clinical target, and the IP being built here will cross over into mainstream MedTech faster than most people would expect.
soft tissue robotics is slowly and quietly becoming the frontier nobody is talking about loudly enough. Johnson & Johnson submitted OTTAVA to the FDA in January 2026 specifically as a soft tissue robotic system, and their May 2026 pivotal clinical data met all primary endpoints.

Side note: because I am a complete medtech nerd, even today while writing this article, I was reading a study freshly published on “Facial Nerve Repair Using a Microsurgical Robot System” - ran by a team of researchers and surgeons in Japan. A procedure that did not even exist few years ago worth reading about.

The competition in surgical robotics is quietly shifting from the platform to what’s at the tip of the arm. End-effectors (modular, haptic-enabled, procedure-specific) are becoming the real differentiation layer. And the access model is changing too: robotics-as-a-service and leasing are opening the door for community hospitals. The specialist robot era isn’t just about which specialty, it’s about what the robot can do, and who can now afford to use it.

What to do: If you’re building or competing in this space, your clinical story needs to be very specific. Map the intersection of underserved specialties and underserved care settings.

3. Women’s Health — the biggest underserved market in MedTech is finally getting attention

For decades, MedTech built products tested primarily on male patients, funded by predominantly male investors, led by predominantly male executive teams, and we called the results “clinical evidence”. Women were systematically underserved by default, and defaults in regulated industries are incredibly hard to change.

That is finally changing! And the market opportunity it’s revealing is enormous.

The global women’s health market size was estimated at $53.48 billion in 2025 and is projected to reach $75.42 billion by 2033, growing at a CAGR of 5.1 % from 2026 to 2033. Women represent the vast majority of healthcare decision-makers, spending nearly 30% more per capita than men on healthcare. And yet, as of 2025, about 75% of clinical trial participants are men. Only 4% of biopharma R&D funding was allocated to conditions specific to women.

This market has been chronically under-researched and under-funded. That is a structural gap that is now becoming a structural opportunity.

VC investment in U.S. and European women’s health companies grew in the last years, and this should send a clear signal to every strategic MedTech player that women’s health commands serious multiples when built with clinical rigor.

FemTech is evolving from wellness and cycle-tracking apps into a data-driven healthcare sector delivering meaningful clinical impact — covering fertility, maternal care, menopause, and digital therapeutics, moving decisively away from generic wellness toward precision and personalization.

Cardiovascular disease in women is underdiagnosed and undertreated. Autoimmune conditions disproportionately affect women. Menopause, which affects 100% of women who live long enough, has essentially no approved device-based interventions. Every one of those is a white space.

What to do: If you’re a Founder, treat women’s health with the same analytical rigor you’d apply to any category with a massive underserved population and growing investor appetite.

4. Agentic AI - From copilot to colleague

In 2024, everyone was talking about generative AI. In 2025, the word “agentic” started appearing in every pitch deck. In 2027, the gap between companies that actually deployed it and companies that are still running pilots will start to show in the numbers.

Hospitals plan to leverage AI primarily for medical record analysis, clinical imaging, and revenue cycles. But here’s where it gets nuanced: while there’s significant promise for agentic AI in healthcare, legacy organizations are always slow to embrace the newest innovations.

The proper infrastructure in majority of the European hospitals is missing.

This is a classic feedback loop problem. AI adoption requires data. Good data requires clean systems. Clean systems require investment. Investment requires demonstrated ROI. But ROI requires adoption. You can see where this gets stuck.

What to do: the companies that will win identified the one decision that, if made 20% faster or more accurately, changes a patient outcome or a margin. Start there.

5. Neurology and Cardiovascular — where the money is flowing

These two therapy areas have always been large. What’s going to change in 2027 is where the innovation is happening, and it’s no longer just implants and ablation catheters.

In neurology, the trend to watch is closed-loop neuromodulation. More closed-loop neuromodulation devices are expected to gain regulatory approval, described as adaptive systems that have shown improved outcomes and show promise for replacing traditional static devices.

Global neurostimulation devices market size was valued at $6.8 billion in 2025. The market is projected to grow from $7.4 billion in 2026 to $14.2 billion by 2034, exhibiting a CAGR of 8.5% during the forecast period. The convergence of neurology with AI-powered imaging, intraoperative navigation, and robotics will be creating entirely new procedural categories.

In cardiovascular, the global market was valued at $74 billion in 2025 and is projected to grow from $79 billion in 2026 to $152 billion by 2035, at a CAGR of 7.5%. That’s a market nearly doubling in a decade — and the growth is not coming from the traditional implants.

Other areas you can keep an eye on:

Pulsed Field Ablation (PFA) - which is considered to be an effective alternative to traditional thermal-based catheter ablation for AFib, with a potentially improved safety profile.

Remote cardiac monitoring - the global market is expected to reach $33 billion by 2034, growing at a CAGR of 10.17%, driven by wearable sensors, mobile applications, and cloud-based analytics enabling real-time tracking outside traditional clinical settings.

What to do: In neurology, watch closed-loop and AI-adaptive systems closely, that’s where differentiation is being built. In cardiovascular, the commercial question is no longer “can we do this procedure?” but “can we do it here, for this payer, with this reimbursement code, in this care setting?”

6. Reimbursement is the new regulatory

Reimbursement is quietly becoming the most important strategic variable in MedTech in 2027. At MedTech World North America 2026, investors and banking leaders said it pretty clearly:

MedTech capital is increasingly flowing toward companies that demonstrate reimbursement strategy, usability, and workflow integration, not just innovation.

That’s a due diligence checklist.

Lawmakers have proposed a reimbursement pathway specifically for AI-enabled devices and the sector needs to get technologies to patients at scale. Medical devices demonstrating lower readmission rates through connected health and proactive data monitoring are now well-positioned with providers and payers as CMS drives adoption of outcomes-based reimbursement.

Read that again. The payer is now asking: does this actually reduce readmissions? Does this actually save staff time? Does this actually change the total cost of care?

The healthcare system is explicitly comparing the future it wants (preventive, distributed, lower cost) with where it is today, and only funding the bridge between those two states.

If your value story is still built around features and clinical specs, you’re selling to the wrong conversation.

What to do: Build your reimbursement strategy into product development, not as a post-approval afterthought. If your product prevents something rather than treats something — learn the language of the total cost of care. And the biggest hidden line item in that total cost of care equation? The people delivering it.

7. The workforce crisis is still a design problem

Everyone keeps talking about the MedTech talent shortage like it’s a pipeline issue - it’s not. If it’s a pipeline problem: you recruit harder, you pay more, and post more LinkedIn jobs.

If it’s a design problem, you have to rebuild: how work is structured, what tools people use, and what the value exchange actually looks like.

According to the World Economic Forum, 60% of the global workforce will need upskilling and reskilling before 2027. The World Manufacturing Foundation reports that 74% of companies face an acute shortage of skilled workers, while 94% expect to hire or repurpose workers through increased smart manufacturing adoption. In MedTech specifically, 45% of frontline manufacturing workers say the opportunity to work in a more modern, digital environment would factor into their decision to leave their current employer.

They’re not leaving because competitors pay more. They’re leaving because the work environment is designed for 1995. Paper-based documentation, manual device history records, systems that require three logins to get one data point. In a world where these people have smartphones, smartwatches, and instant access to everything in their personal lives, they walk into their day-to-day jobs and travel back in time.

The MedTech AI talent gap illustrates this sharply. MedTech hasn’t designed a value proposition competitive with Google, Nvidia, or well-funded digital health startups. They’ve invested so heavily in traditional talent management structures (job bands, annual reviews, siloed LMS training modules, paper-based SOPs) that they keep allocating resources to a system that isn’t working, rather than redesigning it.

What to do: Adjust your environment not just for compliance, but in such way that talent follows modern tools. Build upskilling pathways tied to the actual systems your people use daily, not generic e-learning modules. And the next time someone proposes a new AI initiative, ask: “What’s the people plan for this?” If there isn’t one, the tech plan will fail.

8. The home is the new hospital

I’ve been hearing “hospital at home” for 10 years. The difference in 2027 will be that the clinical evidence will support it at scale, and the reimbursement infrastructure is finally catching up.

The global remote patient monitoring devices market size was valued at $59.92 billion in 2025 and is projected to grow from $71.29 billion in 2026 to $289.77 billion by 2034, exhibiting a CAGR of 19.16% during the forecast period.

Remote patient monitoring can cut hospital readmissions by up to 30%, reduce emergency room visits by up to 78%, and save thousands of $ per patient/annually for the healthcare systems. Readmission reduction data is corroborated in peer-reviewed literature (2025) and NCBI systematic reviews.

Predictive clinical analytics platforms can now forecast potential health events with up to 75% accuracy. Bio-integrated wearables are making continuous data collection seamless. Virtual ward infrastructure, combining real-time physiological alerts with remote nursing oversight, is proving that patients with complex conditions can be safely managed outside the hospital at a fraction of the cost.

The care model shift is from hospital-as-default to home-as-first-choice, hospital-as-last-resort. And this has downstream implications that most MedTech companies have not yet fully modeled.

What to do: Honestly assess what percentage of your addressable market is in the home and ambulatory setting by 2030. If the answer is “significant and growing”, build a parallel commercial pathway now, while your hospital relationships are still strong enough to give you distribution advantages.

9. Longevity and preventive medicine

Five years ago, if you walked into a serious MedTech investor meeting and said “longevity,” you got politely escorted out. It sounded like biohacking. It sounded like wishful thinking dressed up in lab coats.

As per Market Research Future analysis, the Longevity industry is projected to grow from $23.5 billion in 2025 to $63.03 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.37% during the forecast period 2025 - 2035.

The global wellness market is projected to exceed $8.5 trillion by 2027. The longevity economy, specifically aging, prevention, and healthspan extension is projected to reach $1.4 trillion by 2029 at a 12.7% CAGR. What’s actually moving for MedTech specifically? Biological age diagnostics, precision prevention platforms, metabolic health monitoring.

But here’s the honest caution — and this is where I’ll push back on the pure euphoria. Not all longevity bets are created equal. The longevity market still lacks clear regulatory frameworks, standardized outcomes, and unified clinical guidelines. Stanford’s Center on Longevity explicitly flags this in multiple publications.

There is a distinction that matters: the companies winning are those building diagnostics and monitoring tools that plug into existing clinical workflows and generate reimbursable evidence. The companies failing are those building utopian care models that require patients to pay cash and bypass insurance entirely.

What to do: If you’re in diagnostics, remote monitoring, or preventive care - your value story aligns with where institutional capital is moving. Map your product to the longevity framework: does it detect something earlier? Does it change a behavior? Does it prevent an acute event? Those three questions are the investor thesis in this space. And if your answer to all three is yes, get your reimbursement strategy locked before you think about your fundraising.

The bottom line for 2027

Here’s the simplest explanation of where MedTech will be in 2027:

Healthcare is moving from volume to value, from hospital to home, from reactive to preventive, from generic to specific. Every trend in this article is either an accelerant of that shift, or the consequence of resisting it for too long.

The surgical robot niche is the industry finally admitting that “general purpose” was never the right answer for precision medicine. Women’s health is the industry finally correcting a 50-year research debt that was also a 50-year market miss. The longevity thesis is investors finally pricing the economic reality of an aging population into asset allocation. The AI Act is the industry finally being held accountable for the systems it deploys in clinical settings. The reimbursement shift is the industry finally being measured on outcomes instead of volume. The workforce design problem is the industry finally understanding that talent follows the environments, not the salary.

None of this is happening by accident. It’s happening because the pressure (financial, regulatory, clinical, social) has finally exceeded the inertia. The fear of changing a commercial model that works today is blinding them to the model that won’t work in three years.

You don’t need to do everything at once, but you do need to pick the right 1% to start with.

The question isn’t whether you see the next year’s trends. It’s whether your next decision will reflect them.

Hi, I’m Alina. I work with MedTech Founders and C-level executives on the things that make or break a company before it’s visible from the outside — strategy, brand positioning, regulatory readiness, investor narratives, and the messy gap between having a great idea and building a successful company.

Let’s talk: Book a call / Send me a message

Discussion about this post

Ready for more?